Trial Profile
Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2016
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary) ; Pegfilgrastim (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 30 Jun 2016 New trial record